/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.png00esolorio/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.pngesolorio2023-05-23 15:56:282023-05-23 16:03:15Peptilogics Reports Positive 90-Day Top Line Interim Data From Phase 1b Trial of PLG0206 in Patients with Periprosthetic Joint Infection (PJI)
/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.png00David Anderson/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.pngDavid Anderson2023-04-06 05:00:192023-04-06 05:00:25Peptilogics Completes Phase 1b Trial Enrollment and Will Present Interim Top-line Safety and Tolerability Data of PLG0206 in Patients Undergoing DAIR for the Treatment of Periprosthetic Joint Infection After a Total Knee Arthroplasty at ECCMID 2023
/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.png00eallison/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.pngeallison2023-02-23 16:34:512023-02-23 16:43:50Peptilogics Hosting Panel Discussion with Leading Industry Experts on the High Unmet Medical Need and Opportunity in Periprosthetic Joint Infections (PJI)
/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.png00David Anderson/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.pngDavid Anderson2022-10-19 16:48:382022-10-19 16:57:26Peptilogics to Present Data at IDWeek 2022 on PLG0206, an Engineered Antimicrobial Peptide Targeting Bacteria Causing Periprosthetic Joint Infection
/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.png00David Anderson/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.pngDavid Anderson2022-10-06 16:53:592022-10-06 16:57:40Peptilogics Presents Data Demonstrating Antimicrobial Activity Against Difficult to Treat Bacterial Pathogens of Engineered Peptide PLG0206 at the 2022 ASM/ESCMID Joint Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance
/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.png00David Anderson/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.pngDavid Anderson2022-10-05 13:25:452022-10-06 16:56:54Peptilogics Announces First Patient Dosed in Phase 1b Study of PLG0206 for Periprosthetic Joint Infection
/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.png00eallison/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.pngeallison2022-08-09 17:32:442022-08-09 17:46:13Peptilogics Strengthens Leadership Team with Executive Appointments
/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.png00esolorio/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.pngesolorio2022-08-05 12:17:242022-08-05 12:20:26Peptilogics to Participate in Musculoskeletal Infection Society (MSIS) 32nd Annual Open Scientific Meeting in Pittsburgh
/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.png00David Anderson/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.pngDavid Anderson2022-07-19 05:36:532022-07-19 05:45:09Peptilogics Receives FDA Fast Track Designation for PLG0206, an Investigational Peptide Therapeutic in Development for the Treatment of Periprosthetic Joint Infection
/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.png00eallison/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.pngeallison2022-07-11 20:54:252022-07-11 21:25:58Orion Biotechnology and Peptilogics Enter Strategic Research Collaboration to Enable AI-Driven Drug Discovery Against Undrugged GPCR Target
/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.png00David Anderson/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.pngDavid Anderson2022-04-19 15:14:122022-07-28 15:16:13Peptilogics to Present Data Highlighting Designed Antimicrobial Peptide for the Treatment of Periprosthetic Joint Infection (PJI) at ECCMID 2022
/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.png00David Anderson/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.pngDavid Anderson2022-03-22 08:00:412022-04-27 12:48:45Peptilogics’ Presentations at American Academy of Orthopedic Surgeons (AAOS) 2022 Annual Meeting Highlight Peptide Therapeutic PLG0206 for the Treatment of Periprosthetic Joint Infection (PJI)
/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.png00Emily Hennes/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.pngEmily Hennes2022-03-30 17:17:542022-04-27 13:08:15Peptilogics Announces FDA Clearance of Investigational New Drug Application to Initiate Clinical Trial of PLG0206 in Periprosthetic Joint Infection
/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.png00Emily Hennes/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.pngEmily Hennes2022-03-30 17:07:522022-03-30 17:30:45Peptilogics Receives Award from the Cystic Fibrosis Foundation to Investigate PLG0301 and PLG0206 as Potential Dual-Acting Treatments for Lung Infections Associated with Cystic Fibrosis
/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.png00Emily Hennes/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.pngEmily Hennes2022-03-30 16:59:352022-04-27 13:05:50Peptilogics Announces Two Peer-Reviewed Publications on Designed Peptide Therapeutic PLG0206 for Periprosthetic Joint Infection
/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.png00Emily Hennes/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.pngEmily Hennes2021-11-09 10:56:042022-04-27 13:10:14Peptilogics Presents Positive First-in-Human Phase 1 Data for its Lead Engineered Antibacterial Peptide, PLG0206, at IDWeek 2021
/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.png00Emily Hennes/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.pngEmily Hennes2021-11-09 11:16:222022-04-27 13:13:43Peptilogics to Present First-in-Human Phase 1 Clinical Data of PLG0206 at IDWeek 2021
/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.png00Emily Hennes/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.pngEmily Hennes2021-11-09 11:18:332022-04-27 13:15:34Peptilogics and Cerebras Systems Partner on AI Solutions to Advance the Future of Peptide Therapeutics
/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.png00Emily Hennes/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.pngEmily Hennes2021-11-09 11:20:182022-04-27 13:17:37Peptilogics Strengthens Leadership Team with Five Key Strategic Hires
/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.png00Emily Hennes/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.pngEmily Hennes2021-11-09 11:25:192022-04-29 10:24:46Peptilogics Strengthens Leadership Team with Three Strategic Appointments
/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.png00esolorio/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.pngesolorio2023-05-23 15:56:282023-05-23 16:03:15Peptilogics Reports Positive 90-Day Top Line Interim Data From Phase 1b Trial of PLG0206 in Patients with Periprosthetic Joint Infection (PJI)
/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.png00David Anderson/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.pngDavid Anderson2023-04-06 05:00:192023-04-06 05:00:25Peptilogics Completes Phase 1b Trial Enrollment and Will Present Interim Top-line Safety and Tolerability Data of PLG0206 in Patients Undergoing DAIR for the Treatment of Periprosthetic Joint Infection After a Total Knee Arthroplasty at ECCMID 2023
/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.png00eallison/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.pngeallison2023-02-23 16:34:512023-02-23 16:43:50Peptilogics Hosting Panel Discussion with Leading Industry Experts on the High Unmet Medical Need and Opportunity in Periprosthetic Joint Infections (PJI)
/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.png00David Anderson/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.pngDavid Anderson2022-10-19 16:48:382022-10-19 16:57:26Peptilogics to Present Data at IDWeek 2022 on PLG0206, an Engineered Antimicrobial Peptide Targeting Bacteria Causing Periprosthetic Joint Infection
/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.png00David Anderson/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.pngDavid Anderson2022-10-06 16:53:592022-10-06 16:57:40Peptilogics Presents Data Demonstrating Antimicrobial Activity Against Difficult to Treat Bacterial Pathogens of Engineered Peptide PLG0206 at the 2022 ASM/ESCMID Joint Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance
/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.png00David Anderson/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.pngDavid Anderson2022-10-05 13:25:452022-10-06 16:56:54Peptilogics Announces First Patient Dosed in Phase 1b Study of PLG0206 for Periprosthetic Joint Infection
/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.png00eallison/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.pngeallison2022-08-09 17:32:442022-08-09 17:46:13Peptilogics Strengthens Leadership Team with Executive Appointments
/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.png00esolorio/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.pngesolorio2022-08-05 12:17:242022-08-05 12:20:26Peptilogics to Participate in Musculoskeletal Infection Society (MSIS) 32nd Annual Open Scientific Meeting in Pittsburgh
/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.png00David Anderson/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.pngDavid Anderson2022-07-19 05:36:532022-07-19 05:45:09Peptilogics Receives FDA Fast Track Designation for PLG0206, an Investigational Peptide Therapeutic in Development for the Treatment of Periprosthetic Joint Infection
/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.png00eallison/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.pngeallison2022-07-11 20:54:252022-07-11 21:25:58Orion Biotechnology and Peptilogics Enter Strategic Research Collaboration to Enable AI-Driven Drug Discovery Against Undrugged GPCR Target
/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.png00David Anderson/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.pngDavid Anderson2022-04-19 15:14:122022-07-28 15:16:13Peptilogics to Present Data Highlighting Designed Antimicrobial Peptide for the Treatment of Periprosthetic Joint Infection (PJI) at ECCMID 2022
/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.png00David Anderson/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.pngDavid Anderson2022-03-22 08:00:412022-04-27 12:48:45Peptilogics’ Presentations at American Academy of Orthopedic Surgeons (AAOS) 2022 Annual Meeting Highlight Peptide Therapeutic PLG0206 for the Treatment of Periprosthetic Joint Infection (PJI)
/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.png00Emily Hennes/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.pngEmily Hennes2022-03-30 17:17:542022-04-27 13:08:15Peptilogics Announces FDA Clearance of Investigational New Drug Application to Initiate Clinical Trial of PLG0206 in Periprosthetic Joint Infection
/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.png00Emily Hennes/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.pngEmily Hennes2022-03-30 17:07:522022-03-30 17:30:45Peptilogics Receives Award from the Cystic Fibrosis Foundation to Investigate PLG0301 and PLG0206 as Potential Dual-Acting Treatments for Lung Infections Associated with Cystic Fibrosis
/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.png00Emily Hennes/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.pngEmily Hennes2022-03-30 16:59:352022-04-27 13:05:50Peptilogics Announces Two Peer-Reviewed Publications on Designed Peptide Therapeutic PLG0206 for Periprosthetic Joint Infection
/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.png00Emily Hennes/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.pngEmily Hennes2021-11-09 10:56:042022-04-27 13:10:14Peptilogics Presents Positive First-in-Human Phase 1 Data for its Lead Engineered Antibacterial Peptide, PLG0206, at IDWeek 2021
/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.png00Emily Hennes/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.pngEmily Hennes2021-11-09 11:16:222022-04-27 13:13:43Peptilogics to Present First-in-Human Phase 1 Clinical Data of PLG0206 at IDWeek 2021
/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.png00Emily Hennes/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.pngEmily Hennes2021-11-09 11:18:332022-04-27 13:15:34Peptilogics and Cerebras Systems Partner on AI Solutions to Advance the Future of Peptide Therapeutics
/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.png00Emily Hennes/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.pngEmily Hennes2021-11-09 11:20:182022-04-27 13:17:37Peptilogics Strengthens Leadership Team with Five Key Strategic Hires
/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.png00Emily Hennes/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.pngEmily Hennes2021-11-09 11:25:192022-04-29 10:24:46Peptilogics Strengthens Leadership Team with Three Strategic Appointments